Burning Rock Biotech Limited (BNR:NASDAQ) closed at $12.50 on November 17, 2026, down 1.88% on the day. The stock trades 70.0% below its 52-week high of $41.72 and 84.1% above its 52-week low of $6.79. Over the past year, it lost 16.6%. Burning Rock Biotech Limited is part of the Health Care sector.
In 252 trading sessions since November 17, 2025, BNR closed higher on 123 days (49%). Its best day was January 22, 2026 (+32.20%) and its worst was March 13, 2026 (-29.93%). The stock moved 10% or more in a single session 41 times. It opened at least 5% above the previous day's high 2 times.
Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples.
Find more stocks like BNR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.